Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jardiance Outcomes-Based Contracting Push Underway, Armed With CV Claim

Executive Summary

Boehringer Ingelheim agreement with data analytics firm Inovalon and health care consultancy Avalere will support outcomes-based coverage deals.

You may also be interested in...



Pricing Pressure On Drugs To Intensify As Some Enrollee Cost-Shifting Measures Plateau – PwC

Employers’ may also look more at pitting their health plan vendors against each other for cost-saving coverage, meaning drug makers face more pressure to negotiate reimbursement and other new approaches with health plans, a PwC report suggests.

Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too

US labeling for Boehringer/Lilly's SGLT-2 inhibitor empagliflozin includes results from MACE primary endpoint and its individual components in the EMPA-REG trial, but indication statement is limited to CV risk reduction benefit.

Jardiance's Label Expansion Will Change Diabetes Management

US approval of the first cardiovascular label expansion for an anti-diabetic medicine will mark a shift in disease management, says Datamonitor Healthcare analyst Kevin Shannon.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel